A: Dhuwit awis diétung saben siji saham Agilent Corp

Agilent Technologies is overcoming a slump in biopharmaceutical capital expenditures, as evidenced by the cash per share on this GURU.Markets chart, where 6.24 reflects the latest metric value. Moderate demand cyclicality is offset by stable sales of consumables, although US export barriers and electronics supply chain challenges in Asia create certain operational risks.
Rincian analitis perusahaan Agilent Technologies
- rega saham lan prakiraan rega para ahli:
- informasi kapitalisasi pasar:
- indikator kapitalisasi buku:
- informasi babagan utang lan solvabilitas:
Rasio Kabeh Utang marang Dana Pribadi Agilent Technologies|A - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang modal Agilent Technologies, Inc.|A - Utang perusahaan|Utang-utang marang nilai buku Agilent Tech|A - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Agilent|Likuiditas darurat agilent.com
- data bathi bisnis lan rasio investasi:
A - Bathi resik|Proyeksi bathi resik Agilent Technologies|A - Pangali P/E|Kapitalisasi marang proyeksi bathi Agilent Technologies|A - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Agilent Tech|A - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone patang kuartal pungkasan Agilent|A - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan agilent.com|A - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Agilent Technologies
- statistik dodolan lan pendapatan perusahaan:
- data rasio margin:
- rincian posisi dhuwit lan arus kas:
Analisis komprehensif perusahaan:A (Agilent Corp)

Strategic continuity at Agilent Technologies (A) during leadership transitions ensures operational culture stability and a high level of market confidence. By analyzing changes in cash per share, investors assess the business's liquid reserve, which serves as a buffer against external shocks, although excessive cash holdings may constrain the overall return on equity.
Analisis perusahaan pesaing
DGX: Gunggung dhuwit awis saben saham|Dhuwit awis saben saham ILMN|EXAS (exactsciences.com) - Gunggung dhuwit awis saben saham|Revvity Corp - Dhuwit awis saben siji saham|Gunggung dhuwit awis saben saham BIO|Anbio Corp - Dhuwit awis saben saham|Cekelan dhuwit saben saham Sterigenics|QDEL (QuidelOrtho Corp) - Dhuwit awis saben siji saham|OPK: Dhuwit awis diétung saben siji saham|CDNA (CareDx) - Dhuwit awis saben saham|Maravai LifeSciences Holdings, Inc. (MRVI) - Dana dhuwit diétung saben saham|Dana dhuwit saben saham Fulgent Genetics, Inc. (FLGT)|LAB - Cekelan dhuwit saben saham|Dhuwit awis saben saham CTKB (cytekbio.com)|Gunggung dhuwit awis saben saham OSUR|XGN - Dana dhuwit saben saham|MDxHealth (MDXH) - Dhuwit awis saben siji saham|LUCD (Lucid Diagnostics) - Dhuwit awis saben siji saham|Prenetics Global Ltd (PRE) - Dhuwit awis saben saham|Dana dhuwit saben saham Insight Molecular Diagnostics|TRIB: Gunggung dhuwit awis saben saham|Dana dhuwit saben saham ProPhase (PRPH)|AIMD - Cekelan dhuwit saben saham|Dana dhuwit saben saham Co-Diagnostics, Inc. CODX|Dhuwit awis saben saham Heart Test Laboratories HSCS|Biomerica Inc - Dhuwit awis saben saham|Dana dhuwit diétung saben saham cardiodiagnosticsinc.com CDIO|Onconetix Inc (ONCO) - Dana dhuwit saben saham|Dhuwit awis saben lembar saham VRAX (Virax Biolabs Group Ltd)|BJDX (Bluejay) - Dhuwit awis saben saham|Dhuwit awis saben saham Aspira Women's Health|Dhuwit awis saben saham AXDX|CENTOGENE - Dana dhuwit saben siji saham|Dhuwit awis saben saham ENZ (enzo.com)|Dhuwit awis saben saham Fresh2 Group Ltd FRES|GENE - Dana dhuwit saben saham|ME (23andMe Inc.) - Dana dhuwit saben siji saham|PMD: Dhuwit awis saben saham